Literature DB >> 22433057

Combined effect of Hsp90 inhibitor geldanamycin and parthenolide via reactive oxygen species-mediated apoptotic process on epithelial ovarian cancer cells.

Chung S Lee1, Yun J Kim, Seon A Lee, Soon C Myung, Wonyong Kim.   

Abstract

Hsp90 inhibitor geldanamycin and parthenolide have been shown to induce apoptosis in cancer cells. However, the combined effect of geldanamycin and parthenolide on epithelial ovarian cancer cells has not been studied. In respect of cell death process, we investigated the promoting effect of parthenolide on geldanamycin-induced apoptosis in the human epithelial ovarian carcinoma cell lines OVCAR-3 and SK-OV-3. Geldanamycin induced a decrease in Bid, Bcl-2, Bcl-xL and survivin protein levels; an increase in Bax and tumour suppressor p53 levels; loss of the mitochondrial transmembrane potential; cytochrome c release; activation of caspases (-8, -9 and -3); cleavage of PARP-1; and increase in the reactive oxygen species formation. Parthenolide enhanced geldanamycin-induced changes in the apoptosis-related protein levels, reactive oxygen species formation, nuclear damage and cell death. The combined effect was inhibited by the addition of oxidant scavengers. The results suggest that parthenolide may potentiate the apoptotic effect of geldanamycin on ovarian carcinoma cell lines by the activation of the caspase-8- and Bid-dependent pathway and the mitochondria-mediated apoptotic pathway. The apoptosis-promoting effect seems to be mediated by the stimulatory effect on the formation of reactive oxygen species.
© 2012 The Authors Basic & Clinical Pharmacology & Toxicology © 2012 Nordic Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22433057     DOI: 10.1111/j.1742-7843.2012.00883.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  5 in total

1.  Reversing drug resistance of cisplatin by hsp90 inhibitors in human ovarian cancer cells.

Authors:  Zhengmao Zhang; Zhen Xie; Guangyu Sun; Pingfang Yang; Jia Li; Hongfang Yang; Shuang Xiao; Yang Liu; Hongbing Qiu; Lijun Qin; Chao Zhang; Fenghua Zhang; Baoen Shan
Journal:  Int J Clin Exp Med       Date:  2015-05-15

2.  Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells.

Authors:  Shu-Hua Chu; Yue-Wang Liu; Li Zhang; Bei Liu; Li Li; Jun-Zhen Shi; Li Li
Journal:  Mol Biol Rep       Date:  2012-11-08       Impact factor: 2.316

3.  Parthenolide Sensitizes Human Colorectal Cancer Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand through Mitochondrial and Caspase Dependent Pathway.

Authors:  Kieu Thi Thu Trang; Se-Lim Kim; Sang-Bae Park; Seung-Young Seo; Chung-Hwan Choi; Jin-Kyoung Park; Jin-Chang Moon; Soo-Teik Lee; Sang-Wook Kim
Journal:  Intest Res       Date:  2014-01-28

4.  Geldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor.

Authors:  Artur Jurczyszyn; Anna Zebzda; Jacek Czepiel; William Perucki; Stanisława Bazan-Socha; Dorota Cibor; Danuta Owczarek; Marcin Majka
Journal:  J Cancer       Date:  2014-05-31       Impact factor: 4.207

5.  Hsp72 Is an Intracellular Target of the α,β-Unsaturated Sesquiterpene Lactone, Parthenolide.

Authors:  Myungsun Shin; Andrew McGowan; Gabriel J DiNatale; Thanprakorn Chiramanewong; Tianyi Cai; Rebecca E Connor
Journal:  ACS Omega       Date:  2017-10-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.